Due to complexity and multidisciplinary aspects of this proposal, for fulfilling the objectives and activities of the project, Consortium with 4 partners was built-up (2 universities, 1 research-development institute and one private research centre):
- Coordinator (CO) – University of Medicine and Pharmacy “Carol Davila”, Bucharest (UMF CD);
- Partner 1 (P1) – National Institute of Research – Development in Pathology and Biomedical Sciences “Victor Babes”, Bucharest (INCD VB);
- Partner 2 (P2) - University from Bucharest, Faculty of Biology (UB);
- Partner 3 (P3) – Advanced Studies Research Centre S.R.L. (ASRC).
Each partner will carry out complementary activities. Briefly, the following responsibilities were attributed to the partners, according to their expertise:
University of Medicine and Pharmacy “Carol Davila”, Bucharest (UMF CD)
Performing QSAR/QSPR analysis to reach highly predictive models for therapeutic activity in antitumoral/antirheumatic classes, and further in individualized therapies; experimental evaluation the influence of the therapeutic agents on superoxid dismutese activity; assessment of the investigated drugs effects on SOD activity in relevant cellular models.
Partner 1 (P1)
National Institute of Research – Development in Pathology and Biomedical Sciences “Victor Babes”
Set-up of cellular in vitro models for assessing the antineoplasic and antirheumatic activity of the investigated drugs; Experimental evaluation of the effects exerted by the investigated drugs on cellular metabolism and functionality, using tumour cell lines and mononuclear cells, in various conditions of experimental cellular activation. Correlation of data predicted in silico with those obtained in experimental models performed in vitro.
Partner 2 (P2)
University from Bucharest, Faculty of Biology (UB)
Experimental evaluation of the alteration induced by the studied therapeutically agents on GPD kinetic parameters (KM, Vmax), susceptibility to thermal denaturation and on subunit interaction. The assessment of the effects exerted by the investigated drugs on the GPD activity in relevant cellular models (designed and carried out by Partner 1).
Partner 3 (P3)
Advanced Studies Research Center S.R.L. (ASRC)
Developing specific QSAR software for modelling, further applying and improvement.